EP3981761A3 — Intermediates for prodrugs
Assigned to Ascendis Pharma AS · Expires 2022-08-24 · 4y expired
What this patent protects
The present invention relates to synthetic intermediates of formula Act-L whereinAct is a leaving group; and-L is a non-biologically active linker moiety -L<sup>1</sup> represented by formula (I),wherein the dashed line indicates the attachment to the leaving group an…
USPTO Abstract
The present invention relates to synthetic intermediates of formula Act-L whereinAct is a leaving group; and-L is a non-biologically active linker moiety -L<sup>1</sup> represented by formula (I),wherein the dashed line indicates the attachment to the leaving group and wherein R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>3</sup>, R<sup>3a</sup>, X, X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup> have the meaning as indicated in the description and the claims and wherein L<sup>1</sup> is substituted with one to four groups L<sup>2</sup>-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L<sup>2</sup> is a single chemical bond or a spacer; and Z is a carrier group.
Drugs covered by this patent
- Yorvipath (PALOPEGTERIPARATIDE) · Ascendis Pharma Bone
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.